Transarterial Chemoembolization With Drug-eluting Beads Plus Hepatic Arterial Infusion Chemotherapy Versus Hepatic Arterial Infusion Chemotherapy Alone for Large Hepatocellular Carcinoma
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) plus hepatic artery infusion chemotherapy (HAIC) compared with HAIC alone for unresectable large hepatocellular carcinoma (HCC).
• Patients with HCC confirmed by histology/cytology or diagnosed clinically.
• The maximum HCC lesion \> 7 cm.
• Unresectable HCC evaluated by the surgeon team.
• At least one measurable intrahepatic target lesion.
• Patients without cirrhosis, or with cirrhosis but the liver function of Child-Pugh Class A.
• ECOG score of performance status ≤ 1 point.
• Adequate organ and bone marrow function; the blood biochemical examination: platelet count ≥75×10\^9/L, leukocyte \>3.0×10\^9/L, ASL and AST≤5×ULN, creatinine≤1.5×ULN, INR\<1.5 or PT/APTT normal range.
• Life expectancy of at least 3 months.